Sen. Kamala Harris on Tuesday announced a plan to address the soaring cost of prescription drugs by having the federal government set a “fair price,” joining several fellow 2020 hopefuls seeking to tackle rising drug costs.

Under the California Democrat’s “People Over Profit” plan, the Health and Human Services Department would set a “fair price” for prescription drugs whose prices rise by more than the cost of inflation or that sell for cheaper in comparable Organization for Economic Cooperation and Development (OECD) member countries like Canada, the U.K. and Japan.

Meanwhile, Harris’s plan proposes, profits from drugs sold above their fair price would be taxed at 100% and passed back to consumers as rebates. Her future administration would also prevent Big Pharma companies from taking tax deductions for direct-to-consumer advertising expenses, putting the resulting proceeds toward National Institutes of Health funding.

Should Congress not act on Harris’s plan within her hypothetical first 100 days in the Oval Office, the senator said she planned to take executive action to probe overcharging on major prescription drugs. The federal government would intervene with pharmaceutical companies that price-gouge, she said, including by importing cheaper alternatives and by deputizing the U.S. attorney general to prioritize such investigations.

“ ‘As President, I will not stand idly by as Americans pay thousands of dollars for prescription drugs while big pharmaceutical companies rake in massive profits.’ ” — —Sen. Kamala Harris (D-Calif.), a contender for the 2020 Democratic nomination

Harris would use “march-in” rights, which allow the government to rescind a drug company’s patent and license it to a lower-cost rival, for “the most egregious offenders,” she said.

“As President, I will not stand idly by as Americans pay thousands of dollars for prescription drugs while big pharmaceutical companies rake in massive profits,” Harris said in a statement. “This plan puts people over profit by forcing these companies to reduce prices for consumers and holding them accountable when they gouge Americans.”

Among 49 common brand-name prescription drugs in the U.S., 48 of them rose in price between 2012 and 2017, according to a recent JAMA study. The prices of these top-selling drugs had a median 76% increase over the six-year period, the researchers found, with most increasing in price once or twice a year.

“The United States provides drug companies with the strongest patent protections in the world,” the study’s authors wrote, “but legal strategies in the pharmaceutical industry, such as patenting peripheral aspects of a drug that extend exclusivity rights beyond the original patent and delay generic and biosimilar competition, abuse that liberty.”

The cost of brand-name oral medications rose by 9.2% per year between 2008 and 2016, according to research published in January in the journal Health Affairs and highlighted by Harris’s campaign. For brand-name injectable drugs, costs rose by 15.1% annually. Brand-name drugs increased in cost “due to existing drug price inflation,” the researchers found.

Prescription medications comprised around 9.5% of total national health-care expenditures in 2017, according to the Centers for Medicare and Medicaid Services, making them the third-largest health-care expense. Adjusting for inflation, prescription drug spending increased per capita from $90 in 1960 to $1,025 in 2017.

Some 24% of Americans who take prescription medication report difficulty affording their drugs, according to the Kaiser Family Foundation.

Several other 2020 Democratic candidates have introduced plans to combat the rise in prescription drug prices. Sen. Elizabeth Warren of Massachusetts, for example, seeks to allow the federal government to manufacture certain generic prescription drugs. Legislation co-sponsored by Vermont Independent Sen. Bernie Sanders would ensure that prescription drug prices don’t exceed the median price of those in Canada, France, Germany, the U.K. and Japan.

President Trump’s administration, which recently scrapped a proposal to lower drug prices by overhauling rebates paid to pharmacy benefit managers, announced an executive order this month that would let the U.S. purchase drugs based on the lowest price other developed countries pay. Trump also faced a legal challenge this month to a would-be requirement that drug companies disclose their prices in television ads.